Meeting
2023 ASCO Gastrointestinal Cancers Symposium
BAYONET trial: A multicenter phase II trial of staged combination with encorafenib + binimetinib + cetuximab following encorafenib + cetuximab in patients with BRAF V600E-mutant metastatic colorectal cancer.
Authors
Yuki Matsubara
Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan;
Yuki Matsubara , Hideaki Bando , Daisuke Kotani , Yoshinori Kagawa , Kazuaki Harada , Hiroki Osumi , Naoki Izawa , Takeshi Kawakami , Shogen Boku , Toshihiko Matsumoto , Masashi Wakabayashi , Takayuki Yoshino
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Colorectal Cancer,Anal Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
jRCTs031210510
Citation
J Clin Oncol 41, 2023 (suppl 4; abstr TPS271)
DOI
10.1200/JCO.2023.41.4_suppl.TPS271
Abstract #
TPS271
Poster Bd #
P13
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Gastrointestinal Cancers Symposium
TRIDENTE trial: A phase II study of rechallenge with encorafenib, binimetinib, and cetuximab in patients with RAS wild-type/BRAF V600E–mutant metastatic colorectal cancer.
First Author: Daisuke Kotani
Poster
2018 Gastrointestinal Cancers Symposium
BEACON CRC study safety lead-in (SLI) in patients with BRAFV600E metastatic colorectal cancer (mCRC): Efficacy and tumor markers.
First Author: Eric Van Cutsem
![BEACON CRC (binimetinib [BINI], encorafenib [ENCO], and cetuximab [CTX] combined to treat BRAF-mutant metastatic colorectal cancer [mCRC]): A multicenter, randomized, open-label, three-arm phase III study of ENCO plus CTX plus or minus BINI vs irinotecan (IRI)/CTX or infusional 5-fluorouracil/folinic acid/IRI (FOLFIRI)/CTX with a safety lead-in of ENCO + BINI + CTX in patients (Pts) with BRAF<sup>V600E</sup> mCRC.](https://d201v5jt9ylckg.cloudfront.net/199/11943/153243/153243_poster_pv.jpg)
First Author: Sanne Huijberts
Poster
2024 ASCO Gastrointestinal Cancers Symposium
HGCSG1801: A multicenter, prospective, phase II trial of second-line FOLFIRI plus aflibercept in patients with metastatic colorectal cancer (mCRC) refractory to anti-EGFR antibodies.
First Author: Atsushi Ishiguro